English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Daisuke Satoh,a Mariko Ohte,b Tohru Maeda,a,c Katsunori Nakamura,a,b and Tamihide Matsunaga*,a,b a Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University; b Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Science, Nagoya City University; 3–1 Tanabe-dori, Mizuho-ku, Nagoya 467–8603, Japan: and c College of Pharmacy, Kinjo Gakuin University; 1723–2 Ohmori-cho, Moriyama-ku, Nagoya 463–8521, Japan. Received September 9, 2013; accepted December 26, 2013; advance publication released online January 9, 2014

biological and pharmaceutical bulletin

G6PT Inhibition Model Using HL-60 Cells and Induction of ROS Production through PKC/NOX2 Activation: Clinical Condition for Elucidation of Glycogen Storage Disease Type Ib